The most commonly observed dose-dependent adverse reaction is myelosuppression, primarily manifested as leukopenia, which occurs in up to 20% of IBD patients due to TPMT gene polymorphism [44]. This evidence concerns the gene TPMT and inflammatory bowel disease.